Market Overview

Stocks Hitting 52-Week Highs

Share:
Related
Sarepta Says FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C.
Morning Market Movers
FDA extends action date for review of Sarepta's eteplirsen NDA to May 26 (Seeking Alpha)
Related SRDX
SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon
Top 4 Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Sarepta Therapeutics (NASDAQ: SRPT) shares jumped 106.80% to create a new 52-week high of $31.00. Sarepta Therapeutics reported that treatment with its eteplirsen met its primary endpoint in a Phase IIb extension trial in Duchenne muscular dystrophy patients.

SurModics (NASDAQ: SRDX) shares gained 0.42% to touch a new 52-week high of $21.48. SurModics shares have surged 133.77% over the past 52 weeks, while the S&P 500 index has gained 28.63% in the same period.

Rockville Financial (NASDAQ: RCKB) shares rose 1.02% to create a new 52-week high of $12.83. Rockville Financial is estimated to report its Q3 results on October 25.

Ocwen Financial (NYSE: OCN) shares gained 15.16% to create a new 52-week high of $33.35. Ocwen Financial announced its plans to acquire Homeward Residential Holdings from WL Ross & Co LLC.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

 

Related Articles (RCKB + OCN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters